SciSparc Shares Are Trading Higher After the Company Announced It Signed an Exclusive Patent License Agreement With Polyrizon for the Out-licensing of Its SCI-160 Program for the Treatment of Pain.
SciSparc Shares Are Trading Higher After the Company Announced It Signed an Exclusive Patent License Agreement With Polyrizon for the Out-licensing of Its SCI-160 Program for the Treatment of Pain.
SciSparc股份正在交易，公司宣布与Polyrizon签订独家专利许可协议，将其SCI-160方案进行外部许可以治疗疼痛。
SciSparc Shares Are Trading Higher After the Company Announced It Signed an Exclusive Patent License Agreement With Polyrizon for the Out-licensing of Its SCI-160 Program for the Treatment of Pain.
SciSparc股份正在交易，公司宣布与Polyrizon签订独家专利许可协议，将其SCI-160方案进行外部许可以治疗疼痛。